Clinical trial · Observational
The Jinling Cohort
A Prospective, Multicenter Cohort Study of the Multi-omics Liquid Biopsy MCED Test MERCURY in an Average Risk Chinese Population
NCT06011694CI-TRIAL-00069083recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Jinling Cohort is a prospective, multicenter cohort study in which 15,000 eligible individuals aged 45-75 in Nanjing China will be enrolled.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Liquid Biopsy | — | UNRESOLVED | — |
| Multi Cancer Early Screening | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MERCURY test, health questionnaires and annual routine physical exams | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- No Intervention
- description
- Each participant will undergo peripheral blood collection for MERCURY test, health questionnaires and annual routine physical exams once a year for three consecutive years, then followed up two additional years.
- interventionNames
- Other: MERCURY test, health questionnaires and annual routine physical exams
Primary outcomes (1)
- measure
- To evaluate sensitivity, specificity, positive/negative predictive value and other performance measures of the multi-omics liquid biopsy test MERCURY for multi-cancer early detection in average risk population
- timeFrame
- assessed up to 60 months
Secondary outcomes (3)
- measure
- To evaluate how many cancer types the multi-omics liquid biopsy MCED (multi-cancer early detection) test MERCURY can detect and TOO (tumor of origin) accuracy
- timeFrame
- assessed up to 60 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 45 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1、45-75 years of age; 2、Willing and able to undergo blood sample collection, health questionnaires and annual routine physical exams once a year for three consecutive years; 3、Residents in Nanjing; 4、Fully understand the study and able to provide a written informed consent Exclusion Criteria: 1. Pregnant women; 2. Individuals who have history of cancer or current diagnosis of cancer; 3. Individuals who have organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant; 4. Individulas who have blood transfusion within 30 days prior to the blood draw; 5. Individuals who have an acute infection or inflammation within 14 days prior to the blood draw; 6. Individuals who have taken medication with anti-tumor effects within 30 days prior to the blood draw; 7. Individuals who will not be able to comply with the protocol procedures judged by researchers
References
Publications (0)
Data not yet available
No reference posted for this study.